Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Urology > ASCO GU 2021 > Prostate Cancer > Final TITAN trial results favour use of apalutamide

Final TITAN trial results favour use of apalutamide

Presented by
Dr Kim Chi, British Columbia Cancer and Vancouver Prostate Centre, Canada
Conference
ASCO GU 2021
Trial
Phase 3, TITAN
    Apalutamide plus androgen deprivation therapy (ADT) in men with metastatic castration-sensitive prostate cancer (mCSPC) demonstrated improved overall survival (OS) and reduced risk of death compared with placebo.

    The phase 3, randomised, placebo-controlled, double-blind TITAN trial (NCT02489318) investigated whether the addition of apalutamide to ADT would improve radiographic progression-free survival (rPFS) or OS in men with mCSPC [1]. Of the 1,052 participants, 525 received apalutamide, while 527 received a placebo. Investigators performed their first interim analysis after a median follow-up period of 22.7 months. At that time, both OS and rPFS were significantly better in the apalutamide group (OS, HR=0.67; rPFS, HR=0.48) than in the placebo group.

    This analysis coincided with the unblinding of TITAN, giving patients from the placebo arm the opportunity to proceed to the open-label extension phase of the trial. Of the 527 patients in the placebo arm, 208 (39.5%) chose to cross over to receive apalutamide. Dr Kim Chi (British Columbia Cancer and Vancouver Prostate Centre, Canada) presented the TITAN results following the crossover, after nearly 4 years of follow-up.

    The crossover group underwent treatment for a median duration of 15.4 months, as compared with a median treatment duration of 39.3 months for the apalutamide group, and 20.2 months for the placebo group as a whole.

    Final analyses continue to show superior OS outcomes in the apalutamide group; 48-month survival rates were 65% in the apalutamide group versus 52% in the placebo group. This corresponded to a 35% reduction in the risk of death, which became a 48% reduction of death risk with the inclusion of the crossover patients. Health-related quality of life outcomes did not differ between groups, and the safety profile was consistent with that reported previously. Dr Chi concluded that these final results from TITAN support the use of apalutamide in men with mCSPC.

    1. Chi K. Final analysis results from TITAN: A phase III study of apalutamide versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). Abstract 11, ASCO Genitourinary Cancers Symposium, 11–13 February 2021.

     

    Copyright ©2021 Medicom Medical Publishers



    Posted on